Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria
By
- AMS
posted
Jul 17, 2020 06:12 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Rituximab: a safe therapeutic option during the COVID-19 pandemic?
- AMS
Added Jul 30, 2020
Blog Entry
COVID-19 related anagen effluvium
- AMS
Added Jul 16, 2020
Blog Entry
Urticaria and COVID-19 infection: a critical appraisal
- AMS
Added Aug 19, 2020
Blog Entry
Emerging systemic therapies for atopic dermatitis: biologics
- AMS
Added Nov 04, 2020
Blog Entry
Urticaria and COVID-19 infection: a critical appraisal-reply
- AMS
Added Sep 11, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic